Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

cs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the failure to enter into new collaborations on any of its research and development programs in the event that the merger transaction is not consummated, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and the Company's most recent quarterly report on Form 10-Q as well as subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances af
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Campbell, California (PRWEB) March 31, 2015 ... management consulting firm with operations in California, Oregon, ... formal launch of its Merger and Acquisition (M&A) ... , Peter Adams, VP Client Services and M&A ... repeatedly shown that the vast majority of M&A ...
(Date:3/30/2015)... Calif. , March 30, 2015  NuGene ... its subsidiary corporation, NuGene BioPharma, Inc. has added ... Dr. Guan is an internationally recognized ... finishing his college education at Peking University, ... Ph.D. degree from the University of North Carolina, ...
(Date:3/30/2015)...    Intrexon Corporation (NYSE: XON ... Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... exclusive strategic collaboration and license agreement to develop ... therapies. This collaboration advances Merck Serono,s comprehensive, science-driven ... immune system,s natural ability to fight tumors. ...
(Date:3/30/2015)... , March 30, 2015 ... auf    Richmond Pharmacology ist das erste ... Amyloidose-Zentrum am Royal Free Hospital in ... zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem Patienten ... von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer seltenen ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... Cara Therapeutics, Inc.,announced today that it ... funding,to its original $24 million Series C ... was led by new investor, Devon Park ... investors participating,in the round included; Ascent Biomedical ...
... SILVER SPRING, Md., July 24 United,Therapeutics Corporation ... will,release its 2008 second quarter financial results before ... United Therapeutics will host a half-hour teleconference ... Time. The teleconference is accessible,by dialing 1-800-603-1777, with ...
... Agrees to Increase Original Warrant Amount by an Additional ... ... MTA: CTIC) today announced that a single institutional investor,has agreed to purchase, ... conversion price of $0.79 per share, and a,warrant to purchase approximately 28.2 ...
Cached Biology Technology:Cara Therapeutics Secures $12.3 Million in Series C Extension Financing 2Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 2Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants 3
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... Louis, MO Current research provides a novel model for ... al, "Characterization of the KRN cell transfer model of rheumatoid ... mouse," appears in the September 2010 issue of The ... population is affected by rheumatoid arthritis, and women are affected ...
... University in Washington, D.C., have received a five-year, $3.15 million ... new interdisciplinary program in the environmental affects and policy implications ... ... the Integrative Graduate Education and Research Traineeship (IGERT), which enables ...
... to the slate of expertswhich includes military medical ... Partnerships, on September 23, 2010, at the Omni ... a premier opportunity for representatives of the public ... medical partnerships to benefit our nation,s wounded warriors ...
Cached Biology News:Casing the joint 2Carnegie Mellon receives funding to create new program studying environmental impact of nanotechnology 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 3
Homo sapiens palladin...
Request Info...
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: